The Dudley Group
NHS Foundation Trust

Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ

Ref: FOI-052026-0002433

Date: 22nd June 2026

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

I am analysing the usage of intra-vitreal injections or implants by the NHS. I would greatly appreciate if you could answer the following questions.

Please note for both questions, if a patient has received multiple injection/implants in the time period specified of January to April 2026, please count the total number of injections/implants that the Trust has administered. I.e. if a patient has received two injections/implants please count that as two.

Q1: In the 4-months, Jan-Apr26, the following number of units* of the listed intravitreal treatments were issued (by the Ophthalmology Department) for any condition:
***A unit can be an implant, vial or pre-filled syringe**

Indication	Unit Count
Aflibercept - Eylea	95
Aflibercept - Biosimilar	469
Bevacizumab	0
Dexamethasone	103
Faricimab	1643
Fluocinolone acetonide	0
Ranibizumab - including all Biosimilars	180

Q2: In the 4-months, Jan-Apr26, the following number of units* of the listed intravitreal treatments were issued (by the Ophthalmology Department), by condition:**
***A unit can be an implant, vial or pre-filled syringe**
****The only dataset we hold in Pharmacy for indication is the Blueteq system for the approved use of certain biologic and high-cost treatments; therefore, for Q2 we can only count patients with a completed Blueteq for the named condition. Some of the listed treatments are not licensed for the named indications and as such a Bluteq is not required so that information is not included in the dataset available to Pharmacy. Where this is the case, we cannot answer that part of the question, and "No Blueteq Required" has been reported.**

	Unit Count**			
Indication	WET AMD	DMO	RVO	NIU
Aflibercept - Eylea	24	33	25	n/a
Aflibercept - Biosimilar	122	149	107	n/a

Bevacizumab	0	No Blueteq Required	No Blueteq Required	n/a
Dexamethasone	No Blueteq Required	35	47	No Blueteq Required
Faricimab	1001	360	115	n/a
Fluocinolone acetonide	No Blueteq Required	0	No Blueteq Required	No Blueteq Required
Ranibizumab - including all Biosimilars	137	2	28	n/a

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust